Macrogenics (MGNX) Liabilities and Shareholders Equity (2012 - 2026)

Macrogenics (MGNX) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $217.9 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 2.98% year-over-year to $217.9 million in Q1 2026; TTM through Mar 2026 was $990.9 million, a 4.1% increase from a year earlier, with the FY2025 full-year figure at $256.8 million, down 1.84% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $217.9 million, down from $256.8 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for MGNX reached as high as $343.5 million in Q1 2023 and fell as low as $195.3 million in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $261.4 million across 5 years, with a median of $261.7 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 50.19% in 2022 and soared 74.03% in 2023, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $280.5 million in 2022, then increased by 6.4% to $298.4 million in 2023, then slipped by 12.32% to $261.7 million in 2024, then declined by 1.84% to $256.8 million in 2025, then dropped by 15.17% to $217.9 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $217.9 million in Q1 2026, $256.8 million in Q4 2025, and $270.8 million in Q3 2025.